# Project 2: Sparing in Tumor Free Animals

> **NIH NIH P01** · UNIVERSITY OF CALIFORNIA-IRVINE · 2022 · $362,419

## Abstract

PROJECT SUMMARY – PROJECT 2
We are proposing the creation of a research program entitled, “Increasing the therapeutic index of brain tumor
treatment through innovative FLASH radiotherapy (FLASH-RT), focused on translating a novel irradiation (IR)
modality rapidly into the clinic. The overall hypothesis to be tested is whether radiation delivered at ultra high
dose rates (compared to the much lower dose rates used in current clinical practice) can significantly
ameliorate normal tissue complications while maintaining acceptable if not improved tumor control. To test this
hypothesis, the program will deploy a comprehensive series of preclinical studies that will critically evaluate
tumor control, neurocognitive outcomes and resultant radiation injury to the brain following FLASH-RT and
conventional dose rate irradiation. Collectively, these studies will generate the requisite data sets required for
the rapid translation of the novel FLASH irradiation platform to the clinical scenario. Preclinical studies in mice
assessing orthotopic tumor control, cognition, neuronal and vascular structural plasticity, immune-modulation
and oxygen dependent mechanisms of radiation injury are coupled with a clinical trial in GBM dog patients to
inform the oncologists of the potential benefits of this potentially paradigm shifting technology. The objectives
of this program project will be facilitated by the activities conducted by the dosimetry/physics core (Core 2) and
the Neurobehavioral Core (Core 3).
The current project (Project 2) involves a comprehensive series of cognitive, structural and immunological
studies that will elucidate the long-term (up to 6 months) impact of clinically relevant brain tumor treatments on
cognition under carefully controlled conditions. Animals subjected to single fraction IR, multifraction IR, and
multifraction IR +/- TMZ treatment arms will be behaviorally tested then analyzed for some of the critical
neuronal and vascular changes essential for proper cognitive function. For this project, these proof-of-principal,
long-term neurocognitive studies must be made in tumor free animals in the absence of confounding disease,
and will provide the foundation for elucidating the basis normal tissue sparing afforded by FLASH in the
irradiated brain.

## Key facts

- **NIH application ID:** 10415035
- **Project number:** 5P01CA244091-03
- **Recipient organization:** UNIVERSITY OF CALIFORNIA-IRVINE
- **Principal Investigator:** Charles Limoli
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $362,419
- **Award type:** 5
- **Project period:** 2020-06-01 → 2025-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10415035

## Citation

> US National Institutes of Health, RePORTER application 10415035, Project 2: Sparing in Tumor Free Animals (5P01CA244091-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10415035. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*